期刊
SEMINARS IN IMMUNOLOGY
卷 20, 期 5, 页码 286-295出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2008.09.006
关键词
Cancer; Immunotherapy; Antigen; Tolerance; Clinical trial
类别
资金
- Queensland Cancer Fund
- National Health and Medical Research Council of Australia
Progress in tumor immunology has not been translated to effective immunotherapies for cancer. Most of the current effort in basic and clinical research concentrates on generating effective immune responses against model or well characterized antigens, yet vaccines targeting defined antigens have been less clinically successful than those based on whole tumor cells or their extracts. This review considers characteristics of proteins that determine how effectively they might serve as targets of immune control, and how different sources of antigens have fared in clinical trials. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据